Ardelyx faces securities class action over revenue guidance

A securities class action has been filed against Ardelyx and several executives, alleging misleading statements about long-term sales targets and access barriers for XPHOZAH and IBSRELA. The suit says ARDX shares fell about 18% after the company cut IBSRELA guidance and withdrew long-term XPHOZAH revenue guidance.